Physician profile
Andrew Ness
NPI 1356352306
$282.82
in general payments reported to CMS, 2019-2025
7 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $180 · 2020: $72.68 · 2021: $11.50 · 2022: $18.90.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $124.19 | 2019 | |
| Amarin Pharma, INC. | $58.31 | 2020 | |
| Amgen INC. | $33.29 | 2019-2020 | |
| Amag Pharmaceuticals, INC. | $23.65 | 2019 | |
| Abbvie INC. | $18.90 | 2022 | |
| Bioventus LLC | $12.98 | 2019 | |
| Astrazeneca Pharmaceuticals Lp | $11.50 | 2021 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Andrew Ness listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.